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The introduction of atypical antipsychotic drugs (AAPDs), or second-generation
antipsychotics, with clozapine as the prototype, has largely changed the clinicians’
attitudes toward the treatment of mental illnesses including, but not limited to
schizophrenia. Initially, there was optimism that AAPDs would be superior over typical
antipsychotic drugs (TAPDs), or first-generation antipsychotic drugs, in terms of efficacy
in various phenomenological aspects, including cognitive impairment, and less likelihood
of causing adverse events. However, these views have been partly challenged by results
from recent meta-analysis studies. Specifically, cardio-metabolic side effects of AAPDs, in
spite of a relative paucity of extrapyramidal symptoms, may sometimes limit the use of
these agents. Accordingly, attempts have been made to develop newer compounds, e.g.,
lurasidone, with the aim of increasing efficacy and tolerability. Further investigations are
warranted to determine if a larger proportion of patients will be benefitted by treatment
with AAPDs compared to TAPDs in terms of remission and recovery.
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INTRODUCTION
Antipsychotic drugs have been considered to represent a series
of compounds to treat specific symptoms of schizophrenia, i.e.,
positive (delusions, hallucinations, disorganized thoughts, and
etc.) and negative (blunt affect, avolition, social withdrawal, and
etc.) symptoms. Conventional, or “typical,” antipsychotic drugs
(TAPDs) exert antipsychotic effects at doses that cause extrapyra-
midal motor side effects due to dopamine (DA)-D2 receptor
blocking properties. Selective actions on psychotic symptoms,
with less chance to cause extrapyramidal side effects (EPS), have
become possible with the advent of newer class agents, so-called
“atypical antipsychotic drugs (AAPDs)” (Meltzer, 1991a). In
addition to positive symptoms of schizophrenia, which antipsy-
chotic drugs were initially expected to ameliorate, there is a recent
trend to use AAPDs for other psychiatric diseases, e.g., mood
disorders, as discussed below.
The development of antipsychotic drugs has been cou-
pled with more intricate theories on the pathophysiology of
schizophrenia (Meltzer, 1991b). For example, hyperactivity of DA
neurons projecting to the limbic regions, e.g., nucleus accum-
bens and amygdala, has been shown to be associated with positive
symptoms, while a decrease in DA activity in the prefrontal cortex
has been considered to cause negative symptoms (Seeman et al.,
2006). On the other hand, phencyclidine (PCP), an antagonist at
the N-methyl-D-aspartate (NMDA) type glutamate receptor, has
been found to produce schizophrenia-like symptoms. This obser-
vation led to the glutamate hypothesis of the disease, which is
proposed to be linked to the DA hypothesis (Toru et al., 1994).
This article aims to provide theoretical issues on AAPDs in
relation to efficacy for treating psychotic symptoms and cog-
nition, as well as safety and tolerability. Specifically, cognitive
benefits of lurasidone, a novel AAPD are a focus of this paper.
Based on previous discussions (Oliveira et al., 2009; Melnik et al.,
2010; Meltzer, 2013) and updated information on these issues, the
author present a hypothesis for future directions of therapeutics
of schizophrenia and related disorders.
HISTORY OF ANTIPSYCHOTIC DRUGS
The serendipitous discovery of the ability of chlorpromazine to
treat psychomotor excitation of schizophrenia confirmed the con-
cept that the illness is a medical entity related to brain chemistry
(Delay and Deniker, 1955) (Figure 1). The subsequent devel-
opment of haloperidol, also inhibiting psychomotor symptoms,
provided a clue to the pharmacological target shared by most
antipsychotic agents; the DA-D2 receptor (Seeman et al., 2006).
This property of TAPDs (Figure 2) is associated with the inci-
dence of motor dysfunction, e.g., parkinsonisms, akashisia, dys-
tonia and dyskinesia, as well as endocrinological derangements,
e.g., hyperprolactinemia (Sumiyoshi, 2008).
The search for improved medications for schizophrenia led to
the implementation of clozapine, the prototype of AAPDs (Kane
et al., 1988; Meltzer, 1989). Clozapine shows strong blocking
effects for serotonin (5-HT)-5-HT2A and DA-D4 receptors rela-
tive to D2 receptors, which is thought to underlie the ability of this
compound to ameliorate not only positive symptoms, but also
negative symptoms to some extent, without causing EPS (Meltzer
et al., 1989; Stockmeier et al., 1993; Sumiyoshi et al., 1995).
The experience with clozapine prompted the development of
a series of AAPDs with relatively potent 5-HT2A vs. D2 receptor
blocking effects, in an attempt to decrease the likelihood of EPS
and elevation of plasma prolactin (pPRL) levels. Consequently,
risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone,
have been developed (Figure 3). In addition, paliperidone, an
active metabolite of risperidone, as well as lurasidone, asenapine
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FIGURE 1 | Historical overview of the development of antipsychotic
drugs.
FIGURE 2 | Representative typical (first generation) antipsychotic
drugs.
and iloperidone (in the USA), amisulpiride (in Europe), and per-
ospirone and blonanserin (in Japan), have enriched the choice of
AAPDs (Figure 4).
PHARMACOLOGY
The above AAPDs, except amisulpiride, a relatively selective
D2/D3 ligand, share a property of relatively high 5-HT2A vs. D2
receptor affinity (Meltzer et al., 1989; Stockmeier et al., 1993;
Sumiyoshi et al., 1995). Some of them, e.g., clozapine, olanza-
pine and quetiapine, also exhibit considerable affinities for D1,
histamine H1, adrenalin-α1, and muscarinic-M1, receptors, and
etc. (Meltzer et al., 2003; Newman-Tancredi and Kleven, 2011).
Pharmacologic profiles for representative AAPDs can be summa-
rized as eliciting relatively strong affinities for 5-HT1A, 5-HT2C
FIGURE 3 | Atypical (second generation) antipsychotic drugs widely
used.
FIGURE 4 | Atypical (second generation) antipsychotic drugs recently
developed.
and NA-α1 receptors, in addition to 5-HT2A and D2 receptors, as
indicated in Figure 5 (Newman-Tancredi and Kleven, 2011).
Other common pharmacologic features of AAPDs include
the ability to increase extracellular concentrations of DA and
acetylcholine in the prefrontal cortex, as measured by in vivo
microdialysis (Kuroki et al., 1998; Ichikawa et al., 2002). This
property has been associated with beneficial effects of these com-
pounds on negative symptoms and cognitive impairment (Kuroki
et al., 1998; Ichikawa et al., 2002; Meltzer et al., 2003). It should be
noted that the mechanisms of action of antipsychotic drugs were
largely derived from studies using animal models of behavioral
abnormalities, e.g., sensorimotor gating deficits (Swerdlow et al.,
1994).
EFFICACY
GENERAL VIEWS
A recent meta-analysis comparing AAPDs and TAPDs in the
treatment of chronic schizophrenia suggests the advantage of
clozapine, risperidone, olanzapine, and amisulpiride over TAPDs
(Leucht et al., 2009b) for overall efficacy. However, the effect
sizes were small (Leucht et al., 2009b), and specific side effects of
these agents, e.g., hyperprolactinemia for risperidone and weight
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FIGURE 5 | Receptor binding profiles of antipsychotic drugs. A larger pKi value represents a stronger affinity for the particular receptor. [Data from
Newman-Tancredi and Kleven (2011)].
gain/metabolic syndrome for olanzapine and clozapine, should be
considered (Zhang et al., 2013).
For first-episode patients, Zhang et al. (2013) conducted a
meta-analysis of acute, randomized trials with AAPDs vs. TAPDs
comparison. The results indicate AAPDs as a whole showed supe-
rior efficacy for negative symptoms, and that olanzapine and
amisulpiride specifically showed greater benefits than TAPDs
(Zhang et al., 2013).
COGNITION
Patients with schizophrenia demonstrate a 1–2.5 standard devi-
ation decline in performance on neuropsychological tests of a
range of cognitive domains, e.g., several types of memory, exec-
utive function (planning, flexibility of thinking and etc.), atten-
tion/information processing, verbal fluency, and motor function
(Harvey and Keefe, 1997; Keefe et al., 2004) (Figure 6). Cognitive
impairment in schizophrenia has been suggested to largely deter-
mine the outcome for patients (Green, 1996; Addington and
Addington, 2000; Green et al., 2000).
Although TAPDs, e.g., haloperidol, exert detrimental influence
on cognition in healthy subjects (Saeedi et al., 2006; Veselinovic
et al., 2013), there has been controversy about whether AAPDs
are more advantageous over TAPDs for its enhancement in
schizophrenia (Meltzer et al., 1999; Woodward et al., 2005;
Goldberg et al., 2007). Results of the large scale trials, such as
the Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) study, suggest AAPDs may not elicit superiority over
TAPDs on cognition (Keefe et al., 2007). However, observations
in the CATIE trial should be interpreted with caution, as it did not
include a placebo arm, and the results were from chronic patients
(Lieberman et al., 2005).
Besides a trial with chronic schizophrenia (Weickert et al.,
2003), there has been little study on cognition in acute
schizophrenia that includes a placebo arm. Accordingly, we
recently reported a double-blind placebo-controlled trial to
FIGURE 6 | Cognitive impairment of schizophrenia, as evaluated by the
MATRICS Consensus Cognitive Battery–Japanese version. Patients with
schizophrenia (N = 30) demonstrate about a one-standard deviation decline
from the normative value in the performance on tests of several cognitive
domains. Data were obtained from Outpatient Clinic of University of
Toyama Hospital.
examine the effect of lurasidone, a novel AAPD (Meyer et al.,
2009; Sumiyoshi et al., 2013), on cognitive performance in
patients with acute psychosis, followed by a long-term extension
study (Sumiyoshi et al., 2013) (Figure 7).
In the acute study patients were randomized to receive treat-
ment with lurasidone 80mg (N = 125), 160mg (N = 121),
quetiapine 600mg (N = 120), or placebo (N = 122). Subjects
who completed the 6-week treatment were eligible for the
double-blind extension study to receive a once-daily flexible
dose of lurasidone (40–160mg/day; N = 151) or quetiapine
(200–800mg/day; N = 85). Subjects who received placebo in
the acute study were administered lurasidone (40–160mg/day;
N = 56). Cognitive performance was examined with the com-
puterized CogState battery (Pietrzak et al., 2009) at baseline
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FIGURE 7 | Schema of the protocol for the double-blind study of the
effect of lurasidone on cognitive function in patients with acute
schizophrenia (Sumiyoshi et al., 2013; 3rd Asian Congress on
Schizophrenia Research).
FIGURE 8 | UCSD Performance-based Skills Assessment—Brief version
(UPSA-B).
of the acute phase, and after 6, 19, and 32 weeks of treat-
ment. The battery consists of eight tasks that measure verbal
learning, speed of processing, attention/vigilance, visual work-
ing memory, visual memory, spatial working memory, reason-
ing and problem solving, and social cognition (Pietrzak et al.,
2009). The average of standardized Z-scores from each task was
used as the valid neurocognitive composite Z-score. Functional
capacity was evaluated with UCSD Performance-based Skills
Assessment—Brief version (UPSA-B) (Mausbach et al., 2011)
(Figure 8).
At 6 weeks, the change in the neurocognitive composite
Z-score did not differ significantly among all groups in intent-
to-treat population (N = 488). In the evaluable analysis sam-
ple (N = 267) according to pre-specific criteria, lurasidone, at
160mg, was superior to both placebo (p < 0.05, d = 0.367) and
quetiapine XR (p < 0.05, d = 0.411) (Figure 9). Patients with
any of the active treatments elicited greater improvement in the
UPSA-B score than did those given placebo. In the 6-month
extension study, lurasidone, at flexible doses of 40–160mg/day,
FIGURE 9 | Cognitive composite z-scores in double-blind 6-week acute
phase study of lurasidone (LUR) relative to placebo (PBO). Data are
based on LOCF analysis of CogState composite score (standardized
z-score) at week 6 in the evaluable-test sample set (N = 267). ∗P < 0.05,
ANCOVA adjusted for baseline and pooled center.
showed a significantly greater cognitive benefit compared to
quetiapine XR, at flexible doses of 200–800mg/day, at week 32
(p < 0.01, d = 0.57). Mixed effects model analysis demonstrated
significant cross-sectional and longitudinal relationship between
the cognitive composite score and UPSA-B total score.
Data from the placebo-controlled acute phase study provide
robust evidence for the ability of lurasidone to enhance cognitive
function and functional capacity in patients with schizophrenia.
The relatively high rate of subjects who did not provide evaluable
data may be associated with awareness of illness, or insight, of
study participants (Harvey et al., 2013).
In spite of some beneficial effects, discussed above, no treat-
ments have been approved for treating cognitive or nega-
tive symptoms in schizophrenia. Therefore, further efforts are
required in this area.
MOOD DISORDERS
Recently, AAPDs have been used for a variety of psychiatric
conditions, in addition to schizophrenia, e.g., mood disorders,
although the mechanisms underlying their therapeutic effects
remain unknown. So far, the Food and Drug Administration
in the US has approved indications for olanzapine, quetiapine,
risperidone, aripiprazole, and asenapine to treat bipolar disor-
der, as shown in Table 1 (Bobo, 2013; Spielmans et al., 2013). As
for major depressive disorder, a recent meta-analysis (Spielmans
et al., 2013) indicates adjunctive treatment with AAPDs, e.g.,
aripiprazole, olanzapine/fluoxetine, quetiapine, or risperidone,
is effective in reducing depressive symptoms, with small-to-
moderate effect sizes. Olanzapine, quetiapine, and aripiprazole
are indicated to treat major depression (Spielmans et al., 2013),
as shown in Table 2.
OTHER DISEASES
Some AAPDs have been suggested to ameliorate part of
symptoms or caregiver’s burden in other conditions, such as
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Table 1 | Year of approval by FDA of AAPDs for bipolar disorder.
Acute mania/
mixed episodes
Bipolar disorder
maintenance Tx
Acute bipolar
depression
Olanzapine 2000 2004 2003a
Quetiapine 2004 2004b 2008
Risperidone 2003 2009c
Aripiprazole 2004 2004
Asenapine 2007
Lurasidone 2013d
aOlanzapine/flluoxetine combination.
bIn combination with valproate/lithium.
cDepot formulation.
dBoth for monotherapy and in combination with valproate/lithium.
Table 2 | Year of approval for major depression.
Add-on to antidepressants Monotherapy
Quetiapine 2009 Applying
Olanzapine 2009a
Aripiprazole 2007
aOlanzapine/flluoxetine combination.
Alzheimer’s disease (Mohamed et al., 2012), Huntington disease
(Adam and Jankovic, 2008), Parkinson’s disease (Friedman,
2011), and Tourette’s syndrome (Maher and Theodore, 2012).
For example, AAPDs have been reported to reduce psychosis,
agitation, and/or aggressive behavior in Alzheimer’s disease and
Huntington disease (Mohamed et al., 2012; Adam and Jankovic,
2008). Clozapine, as well as quetiapine to some extent, has
been shown to be effective in controlling psychotic symptoms of
Parkinson’s disease (Friedman, 2011).
TOLERABILITY
Compared to TAPDs, AAPDs have been associated with reduced
risk of EPS and tardive dyskinesia, although the latter compounds
may more frequently induce weight gain and cardio-metabolic
side effects in schizophrenia (De Hert et al., 2012a). Further,
some large scale studies with chronic patients did not find notice-
able differences in efficacy between the two antipsychotic classes
(Lieberman et al., 2005; Jones et al., 2006; Leucht et al., 2009a),
raising a question about the advantage of AAPDs. However, there
is a suggestion that higher benefit/risk ratios for AAPDs would
be expected in acute patients compared with chronic patients
(Zhang et al., 2013). In fact, a recent meta-analysis (Zhang et al.,
2013) indicates olanzapine, amisulpiride, risperidone and queti-
apine, elicit superior efficacy, greater treatment persistence and
less EPS than TAPDs. These authors also found greater weight
increase and metabolic changes for some of these AAPDs, such
as olanzapine (Zhang et al., 2013).
These lines of evidence prompted the development of newer
antipsychotic drugs with minimal adverse events associated
with the above AAPDs, e.g., weight gain, lipid metabolism,
cardiovascular risk, and glucose intolerance. Accordingly, the
FDA approved iloperidone and asenapine in 2009, followed
FIGURE 10 | Advantage of atypical antipsychotic drugs (AAPDs) for
improving outcome in the treatment of psychotic disorders. Compared
to typical antipsychotic drugs, AAPDs elicit fewer incidences of
extrapyramidal signs, which enhance compliance and adherence. AAPDs
may also demonstrate greater efficacy for mood symptoms. The superiority
of AAPDs in terms of ameliorating psychotic symptoms and cognitive
impairment is under debate. The development of newer antipsychotic drugs
with minimal adverse events associated with some existing AAPDs, e.g.,
weight gain, cardiovascular symptoms, and hormonal abnormalities, may
provide an effective strategy to attain greater remission rates.
by lurasidone in 2010, for the treatment of adults with acute
schizophrenia. De Hert et al. (2012b) conducted a systematic
review and exploratory meta-analysis of these new AAPDs
together with paliperidone in the treatment of schizophrenia
and bipolar disorder. The findings suggest a relatively greater
tolerability for lurasidone in comparison with placebo, and
indicate the need for further controlled studies comparing the
newer agents with other antipsychotic drugs currently available
(De Hert et al., 2012b).
PERSPECTIVES
In the pursuit of novel therapeutics, critical issues to be addressed,
or “unmet needs,” include (1) treatment-resistant patients, (2)
prevention of psychosis, and (3) remission/recovery. There have
been some suggestions for the former two, e.g., clozapine for
treatment-resistant schizophrenia (Kane et al., 1988; Meltzer,
1989), and risperidone and olanzapine for prevention (McGorry
et al., 2002; McGlashan et al., 2006). On the other hand, there
seems to be a relative paucity of information on whether AAPDs
increase remission in schizophrenia (Takeuchi et al., 2012), due,
partly, to the limited number of valid assessment methods
(Alaqeel and Margolese, 2012).
Such measures include the Remission in Schizophrenia
Working Group (RSWG) criteria (Andreasen et al., 2005), which
has been developed to operationally define symptomatic remis-
sion. Using the RSWG criteria, Alaqeel et al. (2013) recently
conducted a meta-analysis to compare remission rates between
AAPD and TAPD treatments. Results from four eligible studies,
with 3433 schizophrenia patients, suggest AAPDs are associated
with a 1.46 increased probability of attaining remission relative to
TAPDs (Alaqeel et al., 2013). The lower dropout rate with AAPDs
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may explain the modest but significant increase in the rate of
enduring symptomatic remission, which deserves further study.
CONCLUSIONS
Antipsychotic drugs play a major role in the treatment of
schizophrenia and related disorders. However, there remain a
number of issues to be solved to more effectively improve clin-
ical practice, e.g., dealing with treatment-resistant patients. As
discussed, some evidence suggests the superiority of AAPDs as
a group over TAPDs in terms of compliance/adherence, although
controversy exists. At least, it is legitimate to confirm that AAPDs
elicit lower incidence of EPS compared to TAPDs. Accordingly,
AAPDs may also demonstrate greater efficacy for mood symp-
toms, and less likelihood to cause secondary negative symptoms
related to EPS (Figure 10).
Further investigations are warranted to determine if a larger
proportion of patients can be benefitted by treatment with
AAPDs compared with TAPDs in terms of remission and
recovery. Specifically, efforts to develop newer antipsychotic com-
pounds with minimal adverse events associated with some exist-
ing AAPDs, e.g., weight gain, cardiovascular symptoms, and hor-
monal abnormalities, will provide a promising strategy to attain
this goal.
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